June 6, 2024 10:36 AM EDT

Replimune aims for accelerated approval of melanoma therapy; Structure's upsized $476M offering

Replimune aims for accelerated approval of melanoma therapy: The company announced Thursday that one-third of melanoma patients …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Replimune aims for ac­cel­er­at­ed ap­proval of melanoma ther­a­py; Struc­ture's up­sized $476M of­fer­ing